Ironwood Pharmaceuticals (IRWD) Q3 2024 earnings summary

Executive summary

• LINZESS prescription demand grew 13% year-over-year in Q3 2024, marking the seventh consecutive quarter of double-digit new-to-brand growth and reinforcing its strong market position.

• Despite strong volume, LINZESS faced pricing headwinds due to increased Medicaid prescriptions and legislative changes, resulting in a 19% decline in net sales.

• Apraglutide NDA submission remains on track for Q1 2025, targeting adult short bowel syndrome patients on parenteral support, with positive Phase III results and commercial planning advanced.

• Strategic focus is on maximizing LINZESS profits and cash flow while advancing apraglutide and maintaining a strong GI pipeline.

• Ended further recruitment in IW-3300 Phase II study and terminated the CNP-104 collaboration after reviewing Phase II data.

Financial highlights

• LINZESS U.S. net sales were $225.5–$226 million in Q3 2024, down 19% year-over-year; Ironwood revenue was $91.6–$92 million, also down 19%.

• GAAP net income was $3.6–$4 million ($0.02/share); adjusted EBITDA was $26–$26.2 million.

• Operating cash flow for the quarter was $10 million; cash and cash equivalents at quarter-end were $88–$88.2 million.

• Ironwood's share of U.S. LINZESS collaboration revenue was $88.9 million, including a $5.8 million positive adjustment for gross-to-net reserves.

• Commercial margin for LINZESS was 65% in Q3 2024, down from 72% in Q3 2023.

Outlook and guidance

• Full-year 2024 guidance maintained: LINZESS U.S. net sales expected between $900–$950 million, Ironwood revenue $350–$375 million, and adjusted EBITDA greater than $75 million.

• Pricing headwinds anticipated to persist into 2025; detailed guidance to be provided early next year.

• Ongoing R&D and commercial investments are anticipated, particularly for apraglutide and GI-focused programs.

• Cash on hand is expected to be sufficient to meet operating needs for at least the next twelve months.

• Focus remains on disciplined expense management and maximizing profitability.